Indometacin use during study period
| Group 2 (n = 65) | Group 3 (n = 33) | |
|---|---|---|
| Values are number (%). | ||
| Group 2, significant patent ductus arteriosus (PDA) which closed after medical treatment; group 3, significant PDA remaining patent after medical treatment. | ||
| Received indometacin | 58 (89) | 31 (94) |
| Indometacin regimen | ||
| Five doses | 50 (77) | 28 (85) |
| Three doses | 8 (12) | 3 (9) |
| Treatment stopped because of adverse effects | 9 (14) | 4 (12) |
| Multiple number of courses | 12 (18.5) | 10 (30) |